Literature DB >> 9645415

Bone metabolism in patients with systemic lupus erythematosus. Effect of disease activity and glucocorticoid treatment.

M Hansen1, P Halberg, G Kollerup, B Pedersen-Zbinden, K Hørslev-Petersen, L Hyldstrup, I Lorenzen.   

Abstract

The bone metabolism in patients with systemic lupus erythematosus (SLE) has previously been examined, but the results are conflicting. In the present study the bone mineral density (BMD) of the axial and the appendicular skeleton was examined by means of dual energy x-ray absorptiometry. The bone turnover was evaluated by means of biochemical markers in serum and urine in a prospective cohort consisting of 36 female and male SLE patients. Repeated measurements of BMD were performed for up to two years. The BMD was decreased in the hand and in the femoral neck but normal in the spine and in the distal forearm. A weak correlation was found between the BMD of the femoral neck and the total consumption of glucocorticoids. Apart from this finding the BMD was uninfluenced by treatment with glucocorticoids and cyclophosphamide. No significant changes of BMD were found during the follow-up period. The serum concentration of the carboxyterminal cross-linked telopeptide of type I collagen was increased in almost all patients, but no other biochemical markers of bone metabolism were abnormal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9645415     DOI: 10.1080/030097498440813

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  14 in total

1.  Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients.

Authors:  L P C Seguro; C B Casella; V F Caparbo; R M Oliveira; A Bonfa; E Bonfa; R M R Pereira
Journal:  Osteoporos Int       Date:  2014-08-22       Impact factor: 4.507

2.  Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus.

Authors:  J Jacobs; L-A Korswagen; A M Schilder; L H van Tuyl; B A C Dijkmans; W F Lems; A E Voskuyl; I E M Bultink
Journal:  Osteoporos Int       Date:  2012-10-03       Impact factor: 4.507

3.  Bone impairment assessed by HR-pQCT in juvenile-onset systemic lupus erythematosus.

Authors:  J A Paupitz; G L Lima; J C Alvarenga; R M Oliveira; E Bonfa; R M R Pereira
Journal:  Osteoporos Int       Date:  2015-12-22       Impact factor: 4.507

4.  Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators.

Authors:  Gabriela Schmajuk; Edward Yelin; Eliza Chakravarty; Lorene M Nelson; Pantelis Panopolis; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

5.  Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls.

Authors:  I M Gilboe; T K Kvien; G Haugeberg; G Husby
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

6.  A Retrospective Analysis of Longitudinal Changes in Bone Mineral Density in Women with Systemic Lupus Erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Daniela Juárez-Melchor; Pamela Munguía-Realpozo; Ivet Etchegaray-Morales; Nicolás Santiago-Martín; Jorge Ayón-Aguilar; Socorro Méndez-Martínez
Journal:  Calcif Tissue Int       Date:  2021-04-17       Impact factor: 4.333

Review 7.  Bone health in systemic lupus erythematosus.

Authors:  Pantelis Panopalis; Jinoos Yazdany
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

8.  Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Hilda Sandoval-Cruz; Ricardo O Escárcega; Mario Jiménez-Hernández; Ivet Etchegaray-Morales; Elena Soto-Vega; Margarita Muñoz-Guarneros; Aurelio López-Colombo; Margarita Delezé-Hinojosa; Ricard Cervera
Journal:  Clin Rheumatol       Date:  2008-08-01       Impact factor: 2.980

9.  The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

Authors:  H P Bhattoa; P Bettembuk; A Balogh; G Szegedi; E Kiss
Journal:  Osteoporos Int       Date:  2003-12-16       Impact factor: 4.507

10.  Vitamin D deficiency in patients with active systemic lupus erythematosus.

Authors:  V Z C Borba; J G H Vieira; T Kasamatsu; S C Radominski; E I Sato; M Lazaretti-Castro
Journal:  Osteoporos Int       Date:  2008-07-04       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.